Clinical Trials Sponsored by Pfizer ltd

Total 22794 results

Pfizer

Completed

Study Evaluating a 13-valent Pneumococcal Conjugate Vaccine in Preterm Compared to Term Infants.

Premature Birth | Safety | Immunization | 13-valent Pneumococcal Vaccine

Spain, Poland
Pfizer

Completed

A Clinical Trial To Evaluate PF-05089771 On Its Own And As An Add-On Therapy To Pregabalin (Lyrica) For The Treatment Of Pain Due To Diabetic Peripheral Neuropathy (DPN)

Diabetic Neuropathy, Painful

United States
Pfizer

Completed

A Study To Investigate Safety And Efficacy Of CP-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease

Crohn's Disease

Korea, Republic of, Canada, United States, Spain, Netherlands, Australia, Israel, Croatia, Japan, Germany, Hungary, Bulgaria, Austria, Czech Republic, France, Greece, South Africa, Ukraine
Pfizer

Completed

Special Use-Result Surveillance of Unasyn-S (Kit) for Intravenous Use - A Surveillance on High-dose (>6 g Daily) Administration -

Pneumonia | Peritonitis | Lung Abscess
Pfizer

Completed

Drug Use Investigation Of Azithromycin IV For Pneumonia Or Pelvic Inflammatory Disease (Regulatory Post Marketing Commitment Plan) (RESCUE)

Pneumonia | Pelvic Inflammatory Disease
Pfizer

Completed

Safety, Tolerability, and PK of AN2728 in Adolescents With Atopic Dermatitis

Dermatitis, Atopic

United States
Pfizer

Completed

Post Market Surveillance to Observe Safety of Prevenar13™ in Adults

Pneumococcal Disease

Korea, Republic of
Pfizer

Completed

A Safety and Pharmacokinetic Study of CVX-096 in Type 2 Diabetics

Diabetes Mellitus, Type 2

United States
Pfizer

Completed

Study Evaluating On-Demand Treatment Of Xyntha In Chinese Subjects

Hemophilia A

China
Pfizer

Completed

Observational Non-Interventional Study Of Febrile Neutropenia Patients To Evaluate Antibacterial Therapeutical Options

Febrile Neutropenia

Turkey
Pfizer

Completed

Test Re-Test Reliability of [11C]PF-06809247 as a Novel PET Tacer

Neuroinflammation

United States
Pfizer

Completed

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PF-06649751 in Parkinson's Disease

Parkinson's Disease

United States, Belgium
Pfizer

Completed

Intravenous Azithromycin Plus Intravenous Ceftriaxone Followed by Oral Azithromycin With Intravenous Levofloxacin Followed by Oral Levofloxacin for the Treatment of Moderate to Severely Ill Hospitalized Patients With Community Acquired Pneumonia

Community-Acquired Pneumonia (CAP)

United States, Canada, Germany, Greece, Spain
Pfizer

Completed

Use Of Fragmin In Hemodialysis

Chronic Renal Failure

Canada
Pfizer

Completed

A Study to Evaluate the Blood Levels, Safety, and Tolerability of PF-00734200 in Subjects With Impaired Kidney Function and Normal Kidney Function

Renal Insufficiency, Chronic

United States
Pfizer

Completed

A Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Study Of PF-06700841, With Bioavailability/Food Effect Investigation

Plaque Psoriasis

United States
Pfizer

Completed

Safety and Efficacy of AN2728 Topical Ointment, 2% in Children, Adolescents, and Adults (Ages 2 Years and Older) With Atopic Dermatitis

Dermatitis, Atopic

United States
Pfizer

Completed

Study Evaluating the Safety and Efficacy of Enbrel (Etanercept) in Japan

Rheumatoid Arthritis

Japan
Pfizer

Terminated

Study To Determine The Pharmacokinetics Of Sulfasalazine In Children With Juvenile Idiopathic Arthritis

Arthritis, Juvenile Rheumatoid

United States, Mexico
Pfizer

Completed

A Study in Healthy Volunteers to Assess Immune Response to Multiple Injections of Filgrastim Hospira or Neupogen Reference Product.

Healthy Volunteers

United States
Pfizer

Completed

Multiple Dose Study Of PF-04937319 In Patients With Type 2 Diabetes

Diabetes Mellitus, Type 2 | NIDDM

United States
Pfizer

Completed

Study To Understand Efficacy And Safety Of Investigational Agent (PF-04937319) Compared To Approved Agent (Glimepiride) In Patients With Diabetes On Metformin

Diabetes Mellitus, Type 2

Taiwan, United States, Hungary, Canada, Slovakia, India, Bulgaria
Pfizer

Terminated

A Study To Evaluate The Safety And Tolerability Of PF-06342674 (RN168) In Subjects With Multiple Sclerosis (MS)

Multiple Sclerosis

United States
Pfizer

Completed

Study Investigating Rapamune For Post-Marketing Surveillance

Kidney Transplantation

Korea, Republic of
Pfizer

Terminated

POC Study in Partially Responsive Generalized Anxiety Disorder

Generalized Anxiety Disorder

United States
Pfizer

Completed

The Safety And Efficacy Of Maintenance Therapy With CP-690,550

Crohn's Disease

United States, Spain, Israel, Netherlands, Australia, Canada, Japan, Germany, Korea, Republic of, Hungary, Austria, Bulgaria, Czech Republic, Greece, South Africa, Ukraine, France
Pfizer

Completed

A Long-Term, Placebo-Controlled X-Ray Study Investigating the Safety and Efficacy of SD-6010 in Subjects With Osteoarthritis of the Knee (ITIC)

Osteoarthritis

United States, Argentina, Czech Republic, Slovakia, Spain, Belgium, Canada, Peru, Germany, Hungary, Australia, Italy, Poland, Russian Federation
Pfizer

Terminated

A Phase 2, Multi-Center Study To Compare The Efficacy And Safety Of A Chemokine CCR2/5 Receptor Antagonist With Ranibizumab In Adults With Diabetic Macular Edema

Macular Edema, Diabetic

United States, Israel, Germany, Hungary, Bulgaria, Czech Republic, Moldova, Republic of, Poland, Romania
Pfizer

Completed

A Study To Estimate The Effects Of Food On Drug Fesoterodine Fumarate And The Pharmacokinetics Of 5-Hydroxymethyl Tolterodine (5-HMT) In Healthy Volunteers

Urinary Bladder, Overactive

Singapore
Pfizer

Terminated

A Study To Evaluate The Safety And Effects On The Body Of An Investigational Drug Using An Endotoxin-Induced Inflammatory Response Model (POM)

Healthy

United States
Pfizer

Completed

A Study To Assess The Safety And Tolerability Of Different Doses Of PF-06444753 And PF-06444752 In Subjects With Allergic Rhinitis

Allergic Rhinitis

Canada
Pfizer

Completed

13-valent Pneumococcal Conjugate Vaccine Study in Adults and Children in India

Prevention of Pneumonia and Invasive Disease Caused by the Serotypes in 13vPnC

India
Pfizer

Completed

A Study To Evaluate the Safety, Tolerability, And Pharmacokinetics Of PF-06266047 In Healthy Adult Subjects

Healthy Volunteers

Belgium
Pfizer

Terminated

A Study Of The Safety, Tolerability And Effective Of Voriconazole For The Treatment Of Serious Candida Infection And Candida Infection Of The Throat In Pediatric Patients

Candidiasis

Hong Kong, Hungary, China, Czech Republic, Mexico, Philippines, Poland, Slovakia
Pfizer

Terminated

Study Evaluating the Safety and Efficacy of Bapineuzumab in Alzheimer Disease Patients

Alzheimer Disease

United States, Spain, Belgium, France, Australia, Japan, Netherlands, Portugal, Croatia, United Kingdom, Germany, Austria, Sweden, Slovakia, Serbia, Argentina, Italy, Chile, Finland, New Zealand, South Africa, Switzerland, Mexico, Poland
Pfizer

Completed

A 12 Day Study To Evaluate A Topical Drug To Treat Plaque Psoriasis

Psoriasis Vulgaris

Germany
Pfizer

Completed

A Study of PF-06410293 Following Subcutaneous Administration Using A Prefilled Syringe Or A Prefilled Pen In Healthy Adult Subjects (B538-05)

Healthy Subjects

United States
Pfizer

Completed

A Multiple-Dose Study To Evaluate The Pharmacokinetics And Safety Of Voriconazole In Immunocompromised Adolescents

Pharmacokinetics

United States
Pfizer

Terminated

A 6-Week Study To Determine The Safety And Effect Of An Investigational Drug Given With Canagliflozin In Adults With Type 2 Diabetes Mellitus Taking Metformin

Type 2 Diabetes Mellitus

United States
Pfizer

Completed

Study Comparing Bevacizumab + Temsirolimus vs. Bevacizumab + Interferon-Alfa In Advanced Renal Cell Carcinoma Subjects (INTORACT)

Renal Cell Carcinoma

France, Belgium, Hungary, Taiwan, United States, Australia, Spain, Hong Kong, Malaysia, Serbia, Argentina, Brazil, Canada, Chile, Colombia, Czech Republic, Germany, India, Italy, Korea, Republic of, Mexico, Netherlands, Poland, Portugal, Russian Federation and more
Pfizer

Completed

Individualized, Target-Driven Treatment Of Children With Idiopathic Short Stature

Idiopathic Short Stature

United States
Pfizer

Completed

A Study to Evaluate the Pharmacodynamic Effects of Single Oral Doses of PF-06648671 on β-Amyloid (Aβ) Concentrations in Cerebrospinal Fluid (CSF)

Healthy Subjects

United States
Pfizer

Completed

A Phase 1 Study In Japanese Subjects With Type 2 Diabetes Mellitus As Monotherapy

Type 2 Diabetes Mellitus

Japan
Pfizer

Completed

Bosutinib For Autosomal Dominant Polycystic Kidney Disease

Polycystic Kidney, Autosomal Dominant

United States, Canada, Australia, Sweden, Spain, Poland, Korea, Republic of, Switzerland, United Kingdom, Moldova, Republic of, Italy, Czech Republic, Hungary, Lithuania, Romania, Slovakia, Turkey
Pfizer

Completed

Study To Compare Single Dose Of Three Modified Release Formulations Of PF-04937319 With Immediate Release Material-Sparing-Tablet (IR MST) Formulation Previously Studied In Adults With Type 2 Diabetes Mellitus.

Type 2 Diabetes Mellitus

United States
Pfizer

Completed

A Trial to Assess the Safety, Tolerability, and Immunogenicity of Bivalent rLP2086 Vaccine When Given to Healthy Young Adults Aged >=18 to <26 Years. (B1971016)

Healthy

Spain, United States, Finland, Canada, Denmark, Poland
Pfizer

Completed

A Study to Evaluate the Efficacy and Safety of Two Doses of PF-03654746 in Adults With Attention Deficit Hyperactivity Disorder (ADHD).

Attention Deficit Hyperactivity Disorder

United States
Pfizer

Completed

Safety and Efficacy Study of PF-06473871 to Reduce Hypertrophic Scars From Recurring Post-Revision Surgery

Reduction of Hypertrophic Skin Scarring

United States, Germany, Hungary, Spain
Pfizer

Completed

NWP09 in Children With Attention Deficit Hyperactivity Disorder (ADHD)

Attention Deficit Hyperactivity Disorder

United States
Pfizer

Terminated

A Phase 2 Extension Study To Enroll Subjects Who Were Enrolled In B5301001 Study

Hypertrophic Scars Resulting From Prior Breast Scar Revision Surgery

United States

3

Subscribe